Concert Adds Board Member
This article was originally published in Scrip
Executive Summary
Concert Pharmaceuticals Inc. has appointed Meghan FitzGerald to its board of directors and she will serve as a member of its compensation committee – effective March 22, 2016. FitzGerald is currently executive vice president of strategy and policy at Cardinal Health Inc. and prior to this she was president of Cardinal Health Specialty Solutions. Previously she was vice president of new markets international division and business development at Medco Health Solutions Inc. FitzGerald has also held various positions at Pfizer Global Pharmaceuticals.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.